Predicting the toxicity-efficacy ratio of venetoclax in real-world patients
Loïc Osanno(Institut national de recherche en sciences et technologies du numérique), Raphaëlle Fanciullino(Inserm), Laurent Bourguignon, Caroline Solas, Caroline Izard(Centre National de la Recherche Scientifique), Mathilde Dacos(Centre National de la Recherche Scientifique), Laure Farnault(Aix-Marseille Université), Régis Costello(Inserm), Geoffroy Venton(Inserm), Julien Colle(Inserm), Thomas Cluzeau(Centre Hospitalier Universitaire de Nice), Joseph Ciccolini(Centre de Recherche en Cancérologie de Marseille), Pauline Roché(Hôpital de la Conception), Chems Djezzar(Hôpital de la Conception), C. Delpech(Hôpital de la Conception), Lucy Brocque(Hôpital de la Conception), Jacques Chiaroni(Centre National de la Recherche Scientifique)
Cited by 0
Related Papers
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
|Leukemia|2011|464
New insights into the Tyrolean Iceman's origin and phenotype as inferred by whole-genome sequencing
|Nature Communications|2012|464
Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*
|British Journal of Dermatology|2021|414
Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines
|Journal of the American Heart Association|2020|298